Finally AAU Gets NAFDAC’s Nod To Manufacture GLUCOZIL For Diabetes Treatment

Edo state-owned Ambrose Alli University (AAU) Ekpoma, has received approval from the National Agency For Food And Drug Administration And Control (NAFDAC), to manufacture GLUCOZIL for the management and treatment of Diabetes.

The regulatory agency also granted the University both rights of Production and Patents for GLUCOZIL.

The Head of the Department of Pharmacology and the Sub-Dean of Basic Clinical Sciences, College of Medicine of the University,  Dr. Jonathan Emeka Emordi, announced the development on Thursday.

Emordi, who noted that GLUCOZIL is a natural product specifically prepared for the treatment of Diabetes Mellitus, added that as a natural product, GLUCOZIL will cause a regeneration of the beta cells that have been destroyed.

According to him, “If the product is used for a very long period, it will not only manage diabetes but cure it completely.

“GLUCOZIL has a bonus clinical indications for the treatment of BPH, commonly known as enlarged prostate.

“In my analysis of the product, it was discovered that it has the capacity to shrink the prostate so that surgical operations can be avoided.

“The product is scientifically tested, right dose confirmed, safety proven in both humans and animals. It is also capable of flushing the human system. Simply put, it is a detoxifier. It has strong anti-oxidant and anti-inflammatory activities which makes it an immune booster.”

The Acting Vice Chancellor of the University, Prof. Asomwan Sonnie Adagbonyin, who commended Dr. Emordi, said the university’s management is happy with the feat achieved at the College of Medicine and the Department of Pharmacology.

“We are proud of the ranking of our scholars who are determined to excel, do us proud despite the various human and environmental challenges.

“The management is proud of Dr. Emordi and I enjoin other scholars to see his achievement as motivation for them to break new grounds and open new frontiers of knowledge and innovation for the further progress of this University in the super highway of teaching, research and community service,” he said.

Check Also

‎FirstHoldCo Sustains Strong Q1 Momentum As Gross Earnings Hit N942bn … Profit Rises to N321bn; FY Revenue Tops N3.4tn

FirstHoldCo Plc maintained its growth trajectory in the first quarter of 2026, reporting a sharp rise in both revenue and profit as the group’s balance sheet reset began to yield results.

Social Media Auto Publish Powered By : XYZScripts.com